Investor Relations Center
Company profile
Medinice S.A. conducts research and development of innovative medical devices in cardiology. Its main projects include PacePress (a compression band used after implantation of cardiac devices), AtriClamp (a clamp for left atrial appendage closure), and CoolCryo (a cryoapplicator for cardiac surgical ablation). The Company focuses on prototype development, preclinical and clinical testing, and obtaining patents.
Stock price
Medinice S.A. shares have been listed on the Main Market of the Warsaw Stock Exchange since December 30, 2020. Previously, on September 25, 2018, the Company debuted on the NewConnect market.
Sector: medical equipment and supplies
ISIN: PLMDNCE00016
Ticker: ICE
Latest news
- 2025-06-24
CoolCryo FDA Submission for Cardiac Cryoablation
Medinice S.A. has submitted a 510(k) application to the FDA for the CoolCryo system, which enables rapid and effective cardiac cryoablation through the use of liquid nitrogen and a flexible, heated applicator tip. This represents a critical step toward entering the US market and advancing global expansion.
- 2024-12-03
Breakthrough by Polish scientists saving heart disease patients
Medinice plans to introduce innovative medical devices for heart disease patients to the markets of the European Union and the United States. These technologies may shorten hospital stays and reduce treatment costs. Heart diseases already affect 59 million people worldwide, and this number continues to grow.
- 2024-10-16Agreement to subscribe to 1.2m series M shares at 8 PLN each
- 2024-09-27EGM Medinice will decide on October 25, 2024, on the issuance of up to 1.2 million shares for the commercialization of projects
- 2024-09-27Why are we issuing shares now? Medinice in PAP Biznes
- 2024-08-21Talk: An Innovative Approach to Arrhythmia, Medinice in Biznes24.tv See more news
Events and presentations
- May 30, 2025
CoolCryo video for the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2025 conference
- December 12, 2024
Summary of 2024 and Medinice's future development prospects [PL]
Previous events
Latest company reports
- The latest periodic report2025-05-08 17:00
Consolidated quarterly report for Q1-2025 QSr
- The latest current report2025-08-19 11:31 | ESPI 25/2025
Successful completion of the PacePress clinical trial
- 2025-08-01 17:03ESPI | 24/2025Change of the date of publication of the consolidated half-yearly report for the first half of 2025
- 2025-07-30 12:55ESPI | 23/2025Information on the date of registration of shares in series L and L1 shares in KDPW See more reports
Additional information
General MeetingsLearn more
Corporate documentsLearn more
- Investor's calendarTimetable for the Release of Periodic Reports in 2025
- Annual report for 2024: Mar 27, 2025
- Report for Q1-2025: May 8, 2025
- Report for H1-2025: Sept 25, 2025
- Report for Q3-2025: Nov 6, 2025
Leadership TeamLearn more
- Dividend policyOn July 1, 2019, the Management Board of Medinice S.A. adopted a resolution regarding the Company’s dividend policy. In the event that the Company generates a profit eligible for distribution, the Management Board intends to annually submit a proposal to the Ordinary General Meeting for the payment of a dividend, based on the following parameters:
- Profit for distribution and total dividend payout
- 15 - 50 million PLN: at least 50% of profit to be distributed
- 50 - 100 million PLN: at least 60% of profit to be distributed
- Above 100 million PLN: at least 75% of profit to be distributed
Capital Group Structure
Investor contact
Piotr Uchman
Investor Relations Manager
We Care About Your Privacy
Medinice S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.